References
- American Thoracic Society. Cystic Fibrosis. [cited 2016 Aug 02]. Available from: https://www.thoracic.org/patients/patient-resources/breathing-in-america/resources/chapter-7-cystic-fibrosis.pdf.
- Ouyang L, Grosse SD, Amendah DD, et al. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol. 2009;44:989–996. Epub 2009/09/22.
- Chevreul K, Michel M, Brigham KB, et al. Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe. Eur J Health Econ. 2016;17:7–18.
- Mainz J, Narayanan S, Suthoff E, et al. 250 Patient-reported outcomes among patients (pts) with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor (IVA) compared with those homozygous for the F508del-CFTR mutation. J Cystic Fibrosis. 2016;15:S115.
- Simon RH. Cystic fibrosis: overview of the treatment of lung disease. 2016 [cited 2016 August 3]. Available from: https://www.uptodate.com/contents/cystic-fibrosis-overview-of-the-treatment-of-lung-disease?source=search_result&search=cystic+fibrosis+treatment&selectedTitle=1~150
- Hebestreit H, Kieser S, Junge S, et al. Long-term effects of a partially supervised conditioning programme in cystic fibrosis. Eur Respir J. 2010;35:578–583.
- Davies JC, Alton EW, Bush A. Cystic fibrosis. BMJ (Clinical Research Ed). 2007;335:1255–1259. Epub 2007/12/15.
- Arias-Llorente RP, García CB, Martín JJD. The importance of adherence and compliance with treatment in cystic fibrosis. Croatia: INTECH Open Access Publisher; 2012.
- Eakin MN, Riekert KA. The impact of medication adherence on lung health outcomes in cystic fibrosis. Curr Opin Pulm Med. 2013;19:687–691. Epub 2013/09/26.
- Eakin MN, Bilderback A, Boyle MP, et al. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cystic Fibrosis. 2011;10:258–264. Epub 2011/04/05.
- Quittner AL, Zhang J, Marynchenko M, et al. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest J. 2014;146:142–151.
- Harrison MJ, McCarthy M, Fleming C, et al. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF). J Cystic Fibrosis. 2014;13:692–698. Epub 2014/05/13.
- Briesacher BA, Quittner AL, Saiman L, et al. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med. 2011;11:5. Epub 2011/01/22.
- Nasr SZ, Chou W, Villa KF, et al. Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis. J Med Econ. 2013;16:801–808. Epub 2013/03/20.
- Bakker EM, Volpi S, Salonini E, et al. Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation. Eur Respir J. 2011;38:1328–1335. Epub 2011/07/09.
- Ball R, Southern KW, McCormack P, et al. Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week-days during school term-time. J Cystic Fibrosis. 2013;12:440–444. Epub 2013/02/02.
- Rosenfeld M, Davis S, Brumback L, et al. Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety. Pediatr Pulmonol. 2011;46:666–671. Epub 2011/03/03.
- Dentice RL, Elkins MR, Bye PT. Adults with cystic fibrosis prefer hypertonic saline before or during airway clearance techniques: a randomised crossover trial. J Physiother. 2012;58:33–40. Epub 2012/02/22.
- Barker DH, Quittner AL. Parental depression and pancreatic enzymes adherence in children with cystic fibrosis. Pediatrics. 2016;137:e20152296. Epub 2016/01/08.
- Williams E, Edgeworth D, Fantidis M, et al. ePS03.4 Patient reported adherence to ivacaftor. J Cystic Fibrosis. 2015;14:S46.
- Siracusa CM, Ryan J, Burns L, et al. Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor. J Cystic Fibrosis. 2015;14:621–626. Epub 2015/06/16.
- Suthoff ED, Bonafede M, Limone B, et al. Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis. J Med Econ. 2016;19:845-851.
- Modi AC, Cassedy AE, Quittner AL, et al. Trajectories of adherence to airway clearance therapy for patients with cystic fibrosis. J Pediatr Psychol. 2010;35:1028–1037. Epub 2010/03/23.
- Flores JS, Teixeira FA, Rovedder PM, et al. Adherence to airway clearance therapies by adult cystic fibrosis patients. Respir Care. 2013;58:279–285. Epub 2012/07/12.
- Oates GR, Stepanikova I, Gamble S, et al. Adherence to airway clearance therapy in pediatric cystic fibrosis: socioeconomic factors and respiratory outcomes. Pediatr Pulmonol. 2015;50:1244–1252.
- Quittner AL, Zhang J, Marynchenko M, et al. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest. 2014;146:142–151. Epub 2014/02/01.
- Shakkottai A, Kidwell KM, Townsend M, et al. A five-year retrospective analysis of adherence in cystic fibrosis. Pediatr Pulmonol. 2015;50:1224–1229. Epub 2015/09/09.
- Goodfellow NA, Hawwa AF, Reid AJ, et al. Adherence to treatment in children and adolescents with cystic fibrosis: a cross-sectional, multi-method study investigating the influence of beliefs about treatment and parental depressive symptoms. BMC Pulm Med. 2015;15:43. Epub 2015/05/01.
- McCormack P, McNamara PS, Southern KW. A randomised controlled trial of breathing modes for adaptive aerosol delivery in children with cystic fibrosis. J Cystic Fibrosis. 2011;10:343–349. Epub 2011/05/31.
- Quittner AL, Saez-Flores E, Barton JD. The psychological burden of cystic fibrosis. Curr Opin Pulm Med. 2016;22:187–191.
- Riekert K. Promoting adherence and increasing life span. Adv Stud Med. 2009;9:14–19.
- Arrigo T, Rulli I, Sferlazzas C, et al. Pubertal development in cystic fibrosis: an overview. Jpem. 2003;16:267–270.
- Sutton S, Rosenbluth D, Raghavan D, et al. Effects of puberty on cystic fibrosis related pulmonary exacerbations in women versus men. Pediatr Pulmonol. 2014;49:28–35.
- Johansen H, Høiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax. 1992;47:109–111.
- Sawicki GS, Goldman DP, Chan W, et al. Patient preference for treatment administration in cystic fibrosis. Am J Pharm. 2015;7:174–181.
- Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cystic Fibrosis. 2009;8:91–96.
- Ziaian T, Sawyer MG, Reynolds KE, et al. Treatment burden and health‐related quality of life of children with diabetes, cystic fibrosis and asthma. J Paediatr Child Health. 2006;42:596–600.
- O’Donohoe R, Fullen BM. Adherence of subjects with cystic fibrosis to their home program: a systematic review. Respir Care. 2014;59:1731-1746.
- Cystic Fibrosis Foundation. CFTR modulator therapies [cited 2016 Aug 26]. Available from: https://www.cff.org/Living-with-CF/Treatments-and-Therapies/Inhaled-Medications/CFTR-Modulator-Therapies/.
- Modi AC, Quittner AL. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? J Pediatr Psychol. 2006;31:846–858.
- Dalcin P, Rampon G, Pasin LR, et al. Adherence to treatment in patients with cystic fibrosis. J Bras Pneumol. 2007;33:663–670.
- Quittner AL, Assael BM, Bregnballe V, et al. Identify and evaluate tools to measure adherence. [cited 2016 Aug 26]. Available from: https://www.ecfs.eu/files/webfm/webfiles/File/AHP_Nursing%20Research/Clinimetric%20properties%20of%20Adherence_Measures(1).pdf
- Patterson JM, Wall M, Berge J, et al. Gender differences in treatment adherence among youth with cystic fibrosis: development of a new questionnaire. J Cystic Fibrosis. 2008;7:154–164.
- Riekert KA. Medication adherence in cystic fibrosis. Physician’s Weekly. 2014. [cited 2016 Aug 26]. Available from: http://www.physiciansweekly.com/cystic-fibrosis-medication-adherence/
- Bregnballe V, Schiotz PO, Boisen KA, et al. Barriers to adherence in adolescents and young adults with cystic fibrosis: a questionnaire study in young patients and their parents. Patient Prefer Adherence. 2011;5:507–515.
- Schechter MS, Shelton BJ, Margolis PA, et al. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med. 2001;163:1331–1337.
- Dziuban EJ, Saab-Abazeed L, Chaudhry SR, et al. Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis. Pediatr Pulmonol. 2010;45:450–458.
- Knudsen K, Pressler T, Mortensen L, et al. Associations between adherence, depressive symptoms and health-related quality of life in young adults with cystic fibrosis. SpringerPlus. 2016;5:1216.
- Moran A, Brunzell C, Cohen RC, et al. Clinical care guidelines for cystic fibrosis–related diabetes a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33:2697–2708.
- Leslie SR, Gwadry-Sridhar F, Thiebaud P, et al. Calculating medication compliance, adherence and persistence in administrative pharmacy claims databases. Pharm Programming. 2008;1:13-19.
- Yeaw J. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15:728–740.
- Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol. 2013;27:329–340.
- Krass I, Schieback P, Dhippayom T. Adherence to diabetes medication: a systematic review. Diabetic Med. 2015;32:725–737.
- Schaecher KL. The importance of treatment adherence in HIV. Am J Manag Care. 2013;19:s231–7.
- Riekert KA, Eakin MN, Bilderback A, et al. Opportunities for cystic fibrosis care teams to support treatment adherence. J Cystic Fibrosis. 2015;14:142–148.
- Kahana S, Drotar D, Frazier T. Meta-analysis of psychological interventions to promote adherence to treatment in pediatric chronic health conditions. J Pediatr Psychol. 2008;33:590–611.
- Grossoehme DH, Szczesniak RD, Mrug S, et al. Adolescents’ spirituality and cystic fibrosis airway clearance treatment adherence: examining mediators. J Pediatr Psychol. 2016;41:1022–1032. Epub 2016/04/03.
- Grossoehme DH, Szczesniak RD, Britton LL, et al. Adherence determinants in cystic fibrosis: cluster analysis of parental psychosocial, religious, and/or spiritual factors. Ann Am Thorac Soc. 2015;12:838–846. Epub 2015/03/25.
- Grossoehme DH, Opipari-Arrigan L, VanDyke R, et al. Relationship of adherence determinants and parental spirituality in cystic fibrosis. Pediatr Pulmonol. 2012;47:558–566. Epub 2011/12/16.
- Mooney K, Ryan C, Downey DG. Pharmacists’ perspectives on monitoring adherence to treatment in cystic fibrosis. Int J Clin Pharm. 2016;38:296–302.
- George C, Hazle L. Nurses act as a healthcare provider, advocate and educator for CF patients 2014 [cited 2016 Aug 25]. Available from: http://nursing.advanceweb.com/Continuing-Education/CE-Articles/Cystic-Fibrosis.aspx
- Lomas P. Enhancing adherence to inhaled therapies in cystic fibrosis. Ther Adv Respir Dis. 2014;8:39–47.
- Burke T, Dishon S, McEwan L, et al. The evolving role of the multiple sclerosis nurse: an international perspective. Int J MS Care. 2011;13:105–112.
- Marciel KK, Saiman L, Quittell LM, et al. Cell phone intervention to improve adherence: cystic fibrosis care team, patient, and parent perspectives. Pediatr Pulmonol. 2010;45:157–164.
- Nichols DP, Kuk KN, Nick JA. Drug interactions and treatment burden as survival improves. Curr Opin Pulm Med. 2015;21:617–625.
- Sawicki GS, Heller KS, Demars N, et al. Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives. Pediatr Pulmonol. 2015;50:127–136. Epub 2014/03/13.
- Hovstadius B, Petersson G. Non-adherence to drug therapy and drug acquisition costs in a national population-a patient-based register study. BMC Health Serv Res. 2011;11:1.